Joseph Meserve

Title(s)Associate Physician, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Editorial: risk of pneumonia in IBD-reading between the lines! Aliment Pharmacol Ther. 2021 12; 54(11-12):1490-1491. Meserve J, Singh S. PMID: 34741329; PMCID: PMC8601591.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022 Dec; 20(12):2728-2740.e1. Meserve J, Ma C, Dulai PS, Jairath V, Singh S. PMID: 34628078; PMCID: PMC8989719.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Correction to: Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. Dig Dis Sci. 2021 Sep; 66(9):3216. Barsky M, Meserve J, Le H, Collins A, Singh S, Boland B, Sandborn WJ, Dulai PS. PMID: 33555517.
      View in: PubMed   Mentions:    Fields:    
    4. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. Gastroenterology. 2021 07; 161(1):107-115.e3. Meserve J, Luo J, Zhu W, Veeravalli N, Bandoli G, Chambers CD, Singh AG, Boland BS, Sandborn WJ, Mahadevan U, Singh S. PMID: 33744307; PMCID: PMC8238837.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    5. Pathologist, Meet Picasso! Virtual Chromoendoscopy for Detecting Histologic Remission in Ulcerative Colitis. Gastroenterology. 2021 04; 160(5):1469-1472. Meserve J, Singh S. PMID: 33508287; PMCID: PMC8035326.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    6. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Aliment Pharmacol Ther. 2021 02; 53(3):374-382. Meserve J, Facciorusso A, Holmer AK, Annese V, Sandborn WJ, Singh S. PMID: 33314269; PMCID: PMC8041067.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    7. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 01; 20(1):126-135. Lukin D, Faleck D, Xu R, Zhang Y, Weiss A, Aniwan S, Kadire S, Tran G, Rahal M, Winters A, Chablaney S, Koliani-Pace JL, Meserve J, Campbell JP, Kochhar G, Bohm M, Varma S, Fischer M, Boland B, Singh S, Hirten R, Ungaro R, Lasch K, Shmidt E, Jairath V, Hudesman D, Chang S, Swaminath A, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. PMID: 33039584; PMCID: PMC8026779.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    8. Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. Dig Dis Sci. 2021 08; 66(8):2564-2569. Barsky M, Meserve J, Le H, Collins A, Singh S, Boland B, Sandborn WJ, Dulai PS. PMID: 32875527; PMCID: PMC7927417.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    9. Predicting Response to Vedolizumab in Inflammatory Bowel Disease. Front Med (Lausanne). 2020; 7:76. Meserve J, Dulai P. PMID: 32300596; PMCID: PMC7145386.
      View in: PubMed   Mentions: 6  
    10. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 12; 18(13):2952-2961.e8. Dulai PS, Singh S, Vande Casteele N, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A, Koliani-Pace JL, Gao Y, Boland BS, Chang JT, Faleck D, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, Siegel CA, Shen B, Kane S, Loftus EV, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C. PMID: 32062041; PMCID: PMC7899124.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    11. Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflamm Bowel Dis. 2019 10 18; 25(11):1854-1861. Koliani-Pace JL, Singh S, Luo M, Hirten R, Aniwan S, Kochhar G, Chang S, Lukin D, Gao Y, Bohm M, Swaminath A, Gupta N, Shmidt E, Meserve J, Winters A, Chablaney S, Faleck DM, Yang J, Huang Z, Boland BS, Shashi P, Weiss A, Hudesman D, Varma S, Fischer M, Sultan K, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Siegel CA, Dulai PS. PMID: 31050734; PMCID: PMC6799947.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. In the absence of head-to-head trials, what do real world studies tell us about the comparative effectiveness of biologics in Crohn's disease. Best Pract Res Clin Gastroenterol. 2019 Feb - Apr; 38-39:101619. Meserve J, Barsky M, Dulai PS. PMID: 31327408.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 11; 17(12):2497-2505.e1. Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV, Sands BE, Colombel JF, Dulai PS, Ungaro R. PMID: 30625408; PMCID: PMC7026826.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    14. Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 Dec; 113(12):696. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. PMID: 30390030; PMCID: PMC6455086.
      View in: PubMed   Mentions: 1     Fields:    
    15. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 10 12; 24(11):2461-2467. Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS. PMID: 29788240; PMCID: PMC6693035.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    16. Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 07; 17(8):1533-1540.e2. Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. PMID: 30268561; PMCID: PMC6594363.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    17. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 09; 113(9):1345. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. PMID: 29946178; PMCID: PMC6445254.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    18. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. Gastroenterology. 2018 09; 155(3):687-695.e10. Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C. PMID: 29857091; PMCID: PMC6419724.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    19. Disseminated Herpes Simplex Virus with Fulminant Hepatitis. Case Reports Hepatol. 2015; 2015:463825. Rimawi BH, Meserve J, Rimawi RH, Min Z, Gnann JW. PMID: 26290760; PMCID: PMC4531175.
      View in: PubMed   Mentions: 8  
    Joseph's Networks
    Concepts (65)
    Derived automatically from this person's publications.
    _
    Co-Authors (8)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _